Log In
Print
BCIQ
Print
Print this Print this
 

SymlinPen

  Manage Alerts
Collapse Summary General Information
Company Bristol-Myers Squibb Co.
DescriptionPre-filled pramlintide in pen-injector devices
Molecular Target
Mechanism of Action 
Therapeutic ModalityMedical Devices: Drug/device combination
Latest Stage of DevelopmentMarketed
Standard IndicationDiabetes
Indication DetailsTreat Type I and Type II diabetes in patients who have not achieved desired glucose control
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today